LL 37

Drug Profile

LL 37

Alternative Names: LL-37

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karolinska Institute
  • Developer ProMore Pharma
  • Class Anti-infectives; Antiulcers; Peptides
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Inflammation mediator modulators; Keratinocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Leg ulcer

Most Recent Events

  • 05 Oct 2018 9250670: updated KDM and created development lines
  • 01 Oct 2018 Phase-II clinical trials in Leg ulcer in Poland (Topical)
  • 06 Sep 2018 Phase-II clinical trials in Leg ulcer in Sweden (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top